Destiny Pharma (LON: DEST) expects to report on the study results of the phase 2b clinical study on the use of XF-73 nasal gel for the prevention of post-surgical infections by the end of March. finnCap believes that positive news would increase the broker’s valuation of Destiny by 80p a share.
Destiny is a developer of antimicrobial drugs. The main focus has been on XF-73, which is used to treat post-surgical infections, such as MRSA. There are also other potential uses of the XF platform, ...
You are unauthorized to view this page.
